Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Optimized REV-ERB agonists for Chronic Inflammatory Pain

Award Number: R01NS148865
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2031

Group Awards By:

View Award Description

Optimized REV-ERB agonists for Chronic Inflammatory Pain - Project Summary Approximately 20 million Americans are inadequately treated for chronic pain conditions each year. This poses a significant burden to the US economy in lost worker productivity and healthcare costs (~$600 billion annually). Chronic Inflammatory Pain (CIP) is a debilitating condition where pain is elicited by normally innocuous stimuli. CIP develops for a variety of reasons, including tissue injury, recurrent episodes of acute inflammation, cardiovascular or metabolic disease, diabetes, and autoimmune disorders. Current therapeutic options for CIP include NSAIDS, corticosteroids (for short-term treatment due to side effects of chronic use), and opioids. While opioids remain the gold standard for treatment in terms of their efficacy, these drugs are associated with severe side effects including respiratory depression and dependence/abuse, which limits their long-term use and chronic efficacy. We have discovered that pharmacological activation of the nuclear receptor REV-ERB reduces inflammatory pain. Previously, we demonstrated that synthetic REV-ERB agonists do not activate the reward areas of the brain indicating that the abuse potential for REV-ERB agonists should be low. Thus, targeting REV-ERB for development of novel analgesics may be useful. We have developed novel high affinity REV-ERB agonists with in vivo analgesic activity in models of inflammatory pain and the proposed research focuses on optimization of this series of compounds to allow selection of candidates to enter IND enabling studies that would allow their progression to clinical development. This research may provide novel, non-addictive analgesics to treat chronic inflammatory pain.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $603,019 )
2026	2026	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	6/23/2026	NEW	$603,019
														Subtotal = $603,019

Grand Total All Awards = $603,019

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimized REV-ERB agonists for Chronic Inflammatory Pain

Award Number: R01NS148865

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer